PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Dr. Rohan Hockings est le Chief Executive Officer de PYC Therapeutics Ltd, il a rejoint l'entreprise depuis 2016.
Quelle est la performance du prix de l'action PYC THERAPEUTICS LTD. ?
Le prix actuel de PYC THERAPEUTICS LTD. est de $1.07, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de PYC Therapeutics Ltd ?
PYC Therapeutics Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de PYC Therapeutics Ltd ?
La capitalisation boursière actuelle de PYC Therapeutics Ltd est de $1.0B
Est-ce que PYC Therapeutics Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour PYC Therapeutics Ltd, y compris 1 achat fort, 7 achat, 1 maintien, 0 vente et 1 vente forte
